Guadecitabine for AML and MDS: hype or hope?
- 1 September 2015
- journal article
- editorial
- Published by Elsevier in The Lancet Oncology
- Vol. 16 (9) , 1009-1011
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 studyThe Lancet Oncology, 2015
- Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMTBone Marrow Transplantation, 2014
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011
- DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2010
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006